Literature DB >> 465290

Influence of various antihypertensive agents on lifespan of renal hypertensive rats.

Z P Horovitz, M J Antonaccio, B Rubin, R E Panasevich.   

Abstract

1 Daily treatment of two-kidney clipped renal hypertensive rats with hydrallazine, hydrochlorothiazide (HCTZ) and a new orally active inhibitor of the angiotensin-converting enzyme, captopril (SQ14,225), was correlated with survival rates for up to 9 months. 2 The groups of rats given captopril alone or captopril plus intermittent or chronic HCTZ had the best survival rate, whereas HCTZ alone or hydrallazine did not benefically affect survival. 3 Survival rates correlated well with control of BP in these animals.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 465290      PMCID： PMC1429328          DOI： 10.1111/j.1365-2125.1979.tb04696.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  10 in total

1.  SQ 14,225 (D-3-mercapto-2-methylpropanoyl-l-proline), a novel orally active inhibitor of angiotensin I-converting enzyme.

Authors:  B Rubin; R J Laffan; D G Kotler; E H O'Keefe; D A Demaio; M E Goldberg
Journal:  J Pharmacol Exp Ther       Date:  1978-02       Impact factor: 4.030

2.  Effects of propranolol on the development of renovascular hypertension in the rat.

Authors:  A P Niarchos; O P Gulati; O A Carretero
Journal:  Am Heart J       Date:  1977-07       Impact factor: 4.749

3.  Chronic antihypertensive effects of captopril (SQ 14,225), an orally active angiotensin I-converting enzyme inhibitor, in conscious 2-kidney renal hypertensive rats.

Authors:  B Rubin; M J Antonaccio; M E Goldberg; D N Harris; A G Itkin; Z P Horovitz; R E Panasevich; R J Laffan
Journal:  Eur J Pharmacol       Date:  1978-10-15       Impact factor: 4.432

Review 4.  Hypertension. Definitions, natural histories and consequences.

Authors:  G Pickering
Journal:  Am J Med       Date:  1972-05       Impact factor: 4.965

5.  Blood pressure and vascular design in renal hypertension in rats after prolonged propranolol treatment.

Authors:  Y Lundgren
Journal:  Acta Physiol Scand       Date:  1974-07

6.  Effects of propranolol on development and maintanance of severe renal hypertension in rats.

Authors:  F H Leenen; E W Ackerman
Journal:  Clin Exp Pharmacol Physiol       Date:  1976 Nov-Dec       Impact factor: 2.557

7.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Authors:  M A Ondetti; B Rubin; D W Cushman
Journal:  Science       Date:  1977-04-22       Impact factor: 47.728

8.  Central cardiovascular effects of SQ 14,225, an angiotensin-converting enzyme inhibitor in chloralose-anesthetized cats.

Authors:  R R Vollmer; J A Boccagno
Journal:  Eur J Pharmacol       Date:  1977-09-15       Impact factor: 4.432

9.  A specific orally active inhibitor of angiotensin-converting enzyme in man.

Authors:  R K Ferguson; G A Turini; H R Brunner; H Gavras; D N McKinstry
Journal:  Lancet       Date:  1977-04-09       Impact factor: 79.321

10.  Alteration of the course of hypertension in the spontaneously hypertensive rat.

Authors:  E D Freis; D Ragan; H Pillsbury; M Mathews
Journal:  Circ Res       Date:  1972-07       Impact factor: 17.367
  10 in total
  2 in total

Review 1.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

Review 2.  Blockade of the renin-angiotensin system in hypertensive patients with atherosclerotic renal artery stenosis.

Authors:  Faical Jarraya; Menno Pruijm; Gregoire Wuerzner; Michel Burnier
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.